# SHR-A2102 Combined With Adebrelimab as Neoadjuvant Therapy for Early Triple-Negative Breast Cancer

Source: https://onco.cc/trials/nct06819319/  
OnCo record `nct06819319` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of SHR-A2102 and adebrelimab in triple-negative breast cancer, run by Henan Cancer Hospital, not yet recruiting.

## Summary

SHR-A2102 Combined With Adebrelimab as Neoadjuvant Therapy for Early Triple-Negative Breast Cancer is a phase 2, interventional study registered as NCT06819319 by Henan Cancer Hospital, with a registry enrolment figure of 52 participants, started 2025-06-23 and due to reach its primary completion in 2026-12-31. Interventions recorded: SHR-A2102 ; Adebrelimab injection. Conditions listed: TNBC - Triple-Negative Breast Cancer. Triple-negative eligibility wording from the registry: "Triple-negative PD-L1-positive breast cancer:". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT06819319
- Phase: 2
- Setting: A Phase II Study of SHR-A2102 in Combination With Adebrelimab as Neoadjuvant Therapy for Early Triple-Negative Breast Cancer
- Sponsor: Henan Cancer Hospital
- Enrolled: 52

## Sources

- ClinicalTrials.gov NCT06819319: https://clinicaltrials.gov/study/NCT06819319

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Adebrelimab](https://onco.cc/drugs/adebrelimab/), [SHR-A2102](https://onco.cc/drugs/shr-a2102/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06819319.json